Clinical trials
HIV Infections clinical trials
Below are recruiting hiv infections clinical trials, each written for real people, not researchers. We’re tracking 271 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07226323Recruiting
WeCare for mental health and medication adherence in South Africa
This trial tests a counselling program called WeCare to help men who have sex with men in Johannesburg stick to their HIV or PrEP medication and manage depression symptoms. It is designed for those who are struggling with adherence or have unsuppressed HIV.
JohannesburgAges 18 years+ - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT00187512Recruiting
Study of how HIV treatment changes outcomes over time
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
San Francisco, CaliforniaAges 18 years+ - NCT00404989Recruiting
Pregnancy drug safety registry for people with HIV treatment
This trial is a pregnancy registry that collects information about birth outcomes when certain HIV medicines are taken during pregnancy. It helps detect any major birth defects so future pregnancies can be safer.
Wilmington, North CarolinaAges 12–60 - NCT01520844Recruiting
HIV cohort study comparing people on and off treatment
This study follows adults with HIV over time to compare different groups based on how stable their virus levels are. It may help researchers understand who can safely interrupt treatment and who should stay on it, and how immune health changes.
Le Kremlin-BicêtreAges 18–85 - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT04984772Enrolling by invitation
HIV and hepatitis B coinfection follow-up study in Europe
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Ages 16 years+ - NCT06646562RecruitingPhase 4
Long-acting injectable HIV meds for adults 60 and older
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Elche, AlicanteAges 60 years+ - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT02454569Recruiting
Study for people living with HIV willing to join
This study follows people who have tested positive for HIV. It aims to better understand HIV over time, but you can only participate if you agree to join the study.
Battalapalli, Andhra PradeshAges Any age - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT06127290Recruiting
HIV treatment study for people in Eastern Europe and Russia
This study looks at how well newer HIV medicines work in people starting treatment for the first time in Eastern Europe and Russia. It also checks for drug resistance to find better treatment strategies.
CologneAges 18 years+ - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Los Angeles, CaliforniaAges 18 years+ - NCT06834113Recruiting
Testing pain relief from HIV shot location and virtual reality
This study looks at whether changing where you get your HIV injection (in the buttock area) and using a virtual reality headset during the shot can reduce pain. It is for people whose HIV is well-controlled with the injectable medicines cabotegravir and rilpivirine.
Orléans, LoiretAges 18 years+ - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT06762054Recruiting
Better management for dolutegravir-resistant HIV
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
KisumuAges 1 year+ - NCT06747507RecruitingPhase 3
Ndovu study: best HIV treatment for drug resistance
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
KisumuAges 3 years+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT05136703Recruiting
Study depression treatment effects in people living with HIV
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
Coral Gables, FloridaAges 18 years+ - NCT03174977RecruitingEarly Phase 1
How HIV medicine moves through the body on MRI scans
This early study measures how raltegravir (an HIV medicine) spreads in the body using a special scan called PET/MR. It may help doctors better understand how to deliver and monitor HIV treatment, even though it focuses on measuring drug behavior rather than curing HIV.
San Francisco, CaliforniaAges 18 years+ - NCT06507059RecruitingPhase 3
Injectable HIV treatment trial for people with unsuppressed virus
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
KeelungAges 18 years+ - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv infections?
- Yes. Clin2 currently lists 271 recruiting hiv infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.